MacroGenics recently reported strong financial results for 2024, highlighting significant progress in their clinical development milestones. They discussed updates on their business and clinical programs, including advancements in their ADC portfolio and bi-specific MGD024.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing